Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs
Abstract
:1. Introduction
2. Expanding the Understanding of the Origins of Ovarian Cancer
2.1. Origins of High-Grade Serous Ovarian Cancer
2.2. The Fallopian Tube as a Conduit for Genomically Unstable Cells
3. Current Evidence for Opportunistic Salpingectomy
3.1. Screening
3.2. Safety of Salpingectomy
3.3. Effectiveness of Salpingectomy
3.3.1. Historical Studies
3.3.2. Studies of Opportunistic Salpingectomy Performed for Ovarian Cancer Prevention
3.4. Uptake in the General Risk Population
4. The Power of Prevention: Strategies for Scaling Ovarian Cancer Prevention in the Future
4.1. Expanding Access
4.2. Equity
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- American Cancer Society Key Statistics for Ovarian Cancer. Available online: https://www.cancer.org/content/dam/CRC/PDF/Public/8773.00.pdf (accessed on 2 September 2023).
- Köbel, M.; Kalloger, S.E.; Huntsman, D.G.; Santos, J.L.; Swenerton, K.D.; Seidman, J.D.; Gilks, C.B.; British Columbia Canc Agcy; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, V.B. Differences in Tumor Type in Low-Stage Versus High-Stage Ovarian Carcinomas. Int. J. Gynecol. Pathol. 2010, 29, 203–211. [Google Scholar] [CrossRef] [PubMed]
- Auersperg, N. Ovarian Surface Epithelium as a Source of Ovarian Cancers: Unwarranted Speculation or Evidence-Based Hypothesis? Gynecol. Oncol. 2013, 130, 246–251. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2020. CA. Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Bowtell, D.D.; Böhm, S.; Ahmed, A.A.; Aspuria, P.-J.; Bast, R.C.; Beral, V.; Berek, J.S.; Birrer, M.J.; Blagden, S.; Bookman, M.A.; et al. Rethinking Ovarian Cancer II: Reducing Mortality from High-Grade Serous Ovarian Cancer. Nat. Rev. Cancer 2015, 15, 668–679. [Google Scholar] [CrossRef]
- Crum, C.P.; Drapkin, R.; Miron, A.; Ince, T.A.; Muto, M.; Kindelberger, D.W.; Lee, Y. The Distal Fallopian Tube: A New Model for Pelvic Serous Carcinogenesis. Curr. Opin. Obstet. Gynecol. 2007, 19, 3–9. [Google Scholar] [CrossRef]
- Ducie, J.; Dao, F.; Considine, M.; Olvera, N.; Shaw, P.A.; Kurman, R.J.; Shih, I.-M.; Soslow, R.A.; Cope, L.; Levine, D.A. Molecular Analysis of High-Grade Serous Ovarian Carcinoma with and without Associated Serous Tubal Intra-Epithelial Carcinoma. Nat. Commun. 2017, 8, 990–999. [Google Scholar] [CrossRef]
- Karnezis, A.N.; Cho, K.R. Of Mice and Women—Non-Ovarian Origins of “Ovarian” Cancer. Gynecol. Oncol. 2017, 144, 5–7. [Google Scholar] [CrossRef] [PubMed]
- Bolton, K.L.; Chenevix- Trench, G.; Goh, C.; Sadetzki, S.; Ramus, S.J.; Karlan, B.Y.; Lambrechts, D.; Despierre, E.; Barrowdale, D.; McGuffog, L.; et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer. JAMA J. Am. Med. Assoc. 2012, 307, 382–389. [Google Scholar] [CrossRef]
- George, S.H.L.; Garcia, R.; Slomovitz, B.M. Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention. Front. Oncol. 2016, 6, 108. [Google Scholar] [CrossRef]
- Gorodetska, I.; Kozeretska, I.; Dubrovska, A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J. Cancer 2019, 10, 2109–2127. [Google Scholar] [CrossRef]
- Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.-A.; Mooij, T.M.; Roos-Blom, M.-J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA J. Am. Med. Assoc. 2017, 317, 2402–2416. [Google Scholar] [CrossRef] [PubMed]
- Pennington, K.P.; Walsh, T.; Harrell, M.I.; Lee, M.K.; Pennil, C.C.; Rendi, M.H.; Thornton, A.; Norquist, B.M.; Casadei, S.; Nord, A.S.; et al. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Clin. Cancer Res. 2014, 20, 764–775. [Google Scholar] [CrossRef] [PubMed]
- Vergote, I.; González-Martín, A.; Ray-Coquard, I.; Harter, P.; Colombo, N.; Pujol, P.; Lorusso, D.; Mirza, M.R.; Brasiuniene, B.; Madry, R.; et al. European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. Ann. Oncol. 2022, 33, 276–287. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Gu, Y.; Zhang, M.; Shi, X.; Li, Z.; Xu, X.; Sun, T.; Dong, Y.; Xue, C.; Zhu, X.; et al. HRD Effects on First-Line Adjuvant Chemotherapy and PARPi Maintenance Therapy in Chinese Ovarian Cancer Patients. Npj Precis. Oncol. 2023, 7, 51. [Google Scholar] [CrossRef]
- Heitz, F.; Ataseven, B.; Staniczok, C.; Denkert, C.; Rhiem, K.; Hahnen, E.; Heikaus, S.; Moubarak, M.; Welz, J.; Dagres, T.; et al. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer. Cancers 2023, 15, 818. [Google Scholar] [CrossRef]
- Paulet, L.; Trecourt, A.; Leary, A.; Peron, J.; Descotes, F.; Devouassoux-Shisheboran, M.; Leroy, K.; You, B.; Lopez, J. Cracking the Homologous Recombination Deficiency Code: How to Identify Responders to PARP Inhibitors. Eur. J. Cancer 2022, 166, 87–99. [Google Scholar] [CrossRef]
- Hanley, G.E.; Pearce, C.L.; Talhouk, A.; Kwon, J.S.; Finlayson, S.J.; McAlpine, J.N.; Huntsman, D.G.; Miller, D. Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Netw. Open 2022, 5, e2147343. [Google Scholar] [CrossRef]
- Pearce, C.L.; Stram, D.O.; Ness, R.B.; Stram, D.A.; Roman, L.D.; Templeman, C.; Lee, A.W.; Menon, U.; Fasching, P.A.; McAlpine, J.N.; et al. Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiol. Biomark. Prev. 2015, 24, 671–676. [Google Scholar] [CrossRef]
- Menon, U.; Gentry-Maharaj, A.; Burnell, M.; Singh, N.; Ryan, A.; Karpinskyj, C.; Carlino, G.; Taylor, J.; Massingham, S.K.; Raikou, M.; et al. Ovarian Cancer Population Screening and Mortality after Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial. Lancet 2021, 397, 2182–2193. [Google Scholar] [CrossRef]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef]
- Menon, U.; Karpinskyj, C.; Gentry-Maharaj, A. Ovarian Cancer Prevention and Screening. Obstet. Gynecol. 2018, 131, 909–927. [Google Scholar] [CrossRef] [PubMed]
- Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; González-Martín, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Mäenpää, J.; et al. Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the PAOLA-1/ENGOT-Ov25 Trial. Ann. Oncol. 2023, 34, 681–692. [Google Scholar] [CrossRef] [PubMed]
- Garcia, A.; Singh, H. Bevacizumab and Ovarian Cancer. Ther. Adv. Med. Oncol. 2013, 5, 133–141. [Google Scholar] [CrossRef] [PubMed]
- Kuroki, L.; Guntupalli, S.R. Treatment of Epithelial Ovarian Cancer. BMJ 2020, 9, m3773. [Google Scholar] [CrossRef] [PubMed]
- Lopez, J.; Banerjee, S.; Kaye, S.B. New Developments in the Treatment of Ovarian Cancer-Future Perspectives. Ann. Oncol. 2013, 24, 69–76. [Google Scholar] [CrossRef] [PubMed]
- Miller, D.; Finlayson, S. Preventing Ovarian Cancer. OVCARE Res. Program. Vanc. Available online: http://www.ovcare.ca/prevention/preventing_ovarian_cancer/ (accessed on 10 August 2023).
- Eckert, M.A.; Pan, S.; Hernandez, K.M.; Loth, R.M.; Andrade, J.; Volchenboum, S.L.; Faber, P.; Montag, A.; Lastra, R.; Peter, M.E.; et al. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016, 6, 1342–1351. [Google Scholar] [CrossRef] [PubMed]
- Piek, J.M.J.; van Diest, P.J.; Zweemer, R.P.; Jansen, J.W.; Poort-Keesom, R.J.J.; Menko, F.H.; Gille, J.J.P.; Jongsma, A.P.M.; Pals, G.; Kenemans, P.; et al. Dysplastic Changes in Prophylactically Removed Fallopian Tubes of Women Predisposed to Developing Ovarian Cancer. J. Pathol. 2001, 195, 451–456. [Google Scholar] [CrossRef] [PubMed]
- Dubeau, L. The Cell of Origin of Ovarian Epithelial Tumors and the Ovarian Surface Epithelium Dogma: Does the Emperor Have No Clothes? Gynecol. Oncol. 1999, 72, 437–442. [Google Scholar] [CrossRef]
- Lee, Y.; Medeiros, F.; Kindelberger, D.; Callahan, M.J.; Muto, M.G.; Crum, C.P. Advances in the Recognition of Tubal Intraepithelial Carcinoma: Applications to Cancer Screening and the Pathogenesis of Ovarian Cancer. Adv. Anat. Pathol. 2006, 13, 1–7. [Google Scholar] [CrossRef]
- Medeiros, F.; Muto, M.G.; Lee, Y.; Elvin, J.A.; Callahan, M.J.; Feltmate, C.; Garber, J.E.; Cramer, D.W.; Crum, C.P. The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women with Familial Ovarian Cancer Syndrome. Am. J. Surg. Pathol. 2006, 30, 230–236. [Google Scholar] [CrossRef]
- Folkins, A.K.; Jarboe, E.A.; Saleemuddin, A.; Lee, Y.; Callahan, M.J.; Drapkin, R.; Garber, J.E.; Muto, M.G.; Tworoger, S.; Crum, C.P. A Candidate Precursor to Pelvic Serous Cancer (P53 Signature) and Its Prevalence in Ovaries and Fallopian Tubes from Women with BRCA Mutations. Gynecol. Oncol. 2008, 109, 168–173. [Google Scholar] [CrossRef] [PubMed]
- Kuhn, E.; Kurman, R.J.; Vang, R.; Sehdev, A.S.; Han, G.; Soslow, R.; Wang, T.-L.; Shih, I.-M. TP53 Mutations in Serous Tubal Intraepithelial Carcinoma and Concurrent Pelvic High-Grade Serous Carcinoma-Evidence Supporting the Clonal Relationship of the Two Lesions. J. Pathol. 2012, 226, 421–426. [Google Scholar] [CrossRef] [PubMed]
- Saleemuddin, A.; Folkins, A.K.; Garrett, L.; Garber, J.; Muto, M.G.; Crum, C.P.; Tworoger, S. Risk Factors for a Serous Cancer Precursor (“P53 Signature”) in Women with Inherited BRCA Mutations. Gynecol. Oncol. 2008, 111, 226–232. [Google Scholar] [CrossRef] [PubMed]
- Jarboe, E.; Folkins, A.; Nucci, M.R.; Kindelberger, D.; Drapkin, R.; Miron, A.; Lee, Y.; Crum, C.P. Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification. Int. J. Gynecol. Pathol. 2008, 27, 1–9. [Google Scholar] [CrossRef]
- Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.; et al. A Candidate Precursor to Serous Carcinoma That Originates in the Distal Fallopian Tube (J Pathol 2007; 211: 26–35). J. Pathol. 2007, 213, 116. [Google Scholar] [CrossRef]
- Labidi-Galy, S.I.; Papp, E.; Hallberg, D.; Niknafs, N.; Adleff, V.; Noe, M.; Bhattacharya, R.; Novak, M.; Jones, S.; Phallen, J.; et al. High Grade Serous Ovarian Carcinomas Originate in the Fallopian Tube. Nat. Commun. 2017, 8, 1093. [Google Scholar] [CrossRef] [PubMed]
- Kurman, R.J.; Shih, I.-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am. J. Surg. Pathol. 2010, 34, 433–443. [Google Scholar] [CrossRef] [PubMed]
- Carlson, J.W.; Jarboe, E.A.; Kindelberger, D.; Nucci, M.R.; Hirsch, M.S.; Crum, C.P. Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and Its Implications. Int. J. Gynecol. Pathol. 2010, 29, 310–314. [Google Scholar] [CrossRef]
- Visvanathan, K.; Vang, R.; Shaw, P.; Gross, A.; Soslow, R.; Parkash, V.; Shih, I.-M.; Kurman, R.J. Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features: A Reproducibility Study. Am. J. Surg. Pathol. 2011, 35, 1766–1775. [Google Scholar] [CrossRef]
- Powell, C.B.; Swisher, E.M.; Cass, I.; McLennan, J.; Norquist, B.; Garcia, R.L.; Lester, J.; Karlan, B.Y.; Chen, L. Long Term Follow up of BRCA1 and BRCA2 Mutation Carriers with Unsuspected Neoplasia Identified at Risk Reducing Salpingo-Oophorectomy. Gynecol. Oncol. 2013, 129, 364–371. [Google Scholar] [CrossRef]
- Mingels, M.J.J.M.; Roelofsen, T.; van der Laak, J.A.W.M.; de Hullu, J.A.; van Ham, M.A.P.C.; Massuger, L.F.A.G.; Bulten, J.; Bol, M. Tubal Epithelial Lesions in Salpingo-Oophorectomy Specimens of BRCA-Mutation Carriers and Controls. Gynecol. Oncol. 2012, 127, 88–93. [Google Scholar] [CrossRef] [PubMed]
- Bogaerts, J.M.A.; Steenbeek, M.P.; van Bommel, M.H.D.; Bulten, J.; van der Laak, J.A.W.M.; de Hullu, J.A.; Simons, M. Recommendations for Diagnosing STIC: A Systematic Review and Meta-Analysis. Virchows Arch. Int. J. Pathol. 2022, 480, 725–737. [Google Scholar] [CrossRef] [PubMed]
- Weinberger, V.; Bednarikova, M.; Cibula, D.; Zikan, M. Serous Tubal Intraepithelial Carcinoma (STIC)—Clinical Impact and Management. Expert. Rev. Anticancer. Ther. 2016, 16, 1311–1321. [Google Scholar] [CrossRef] [PubMed]
- Shaw, P.A.; Rouzbahman, M.; Pizer, E.S.; Pintilie, M.; Begley, H. Candidate Serous Cancer Precursors in Fallopian Tube Epithelium of BRCA1/2 Mutation Carriers. Mod. Pathol. 2009, 22, 1133–1138. [Google Scholar] [CrossRef]
- Malmberg, K.; Klynning, C.; Flöter-Rådestad, A.; Carlson, J.W. Serous Tubal Intraepithelial Carcinoma, Chronic Fallopian Tube Injury, and Serous Carcinoma Development. Virchows Arch. Int. J. Pathol. 2016, 468, 707–713. [Google Scholar] [CrossRef]
- Howitt, B.E.; Hanamornroongruang, S.; Lin, D.I.; Conner, J.E.; Schulte, S.; Horowitz, N.; Crum, C.P.; Meserve, E.E. Evidence for a Dualistic Model of High-Grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma. Am. J. Surg. Pathol. 2015, 39, 287–293. [Google Scholar] [CrossRef]
- Chen, F.; Gaitskell, K.; Garcia, M.; Albukhari, A.; Tsaltas, J.; Ahmed, A. Serous Tubal Intraepithelial Carcinomas Associated with High-grade Serous Ovarian Carcinomas: A Systematic Review. BJOG Int. J. Obstet. Gynaecol. 2017, 124, 872–878. [Google Scholar] [CrossRef]
- Perets, R.; Wyant, G.A.; Muto, K.W.; Bijron, J.G.; Poole, B.B.; Chin, K.T.; Chen, J.Y.H.; Ohman, A.W.; Stepule, C.D.; Kwak, S.; et al. Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. Cancer Cell 2013, 24, 751–765. [Google Scholar] [CrossRef]
- Visvanathan, K.; Shaw, P.; May, B.J.; Bahadirli-Talbott, A.; Kaushiva, A.; Risch, H.; Narod, S.; Wang, T.-L.; Parkash, V.; Vang, R.; et al. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prev. Res. Phila. Pa. 2018, 11, 697–705. [Google Scholar] [CrossRef]
- Karnezis, A.N.; Cho, K.R.; Gilks, C.B.; Pearce, C.L.; Huntsman, D.G. The Disparate Origins of Ovarian Cancers: Pathogenesis and Prevention Strategies. Nat. Rev. Cancer 2017, 17, 65–74. [Google Scholar] [CrossRef]
- Singh, N.; Gilks, C.B.; Wilkinson, N.; McCluggage, W.G. The Secondary Müllerian System, Field Effect, BRCA, and Tubal Fimbria: Our Evolving Understanding of the Origin of Tubo-Ovarian High-Grade Serous Carcinoma and Why Assignment of Primary Site Matters. Pathology 2015, 47, 423–431. [Google Scholar] [CrossRef] [PubMed]
- Soong, T.R.; Howitt, B.E.; Horowitz, N.; Nucci, M.R.; Crum, C.P. The Fallopian Tube, “Precursor Escape” and Narrowing the Knowledge Gap to the Origins of High-Grade Serous Carcinoma. Gynecol. Oncol. 2019, 152, 426–433. [Google Scholar] [CrossRef] [PubMed]
- Shih, I.-M.; Wang, Y.; Wang, T.-L. The Origin of Ovarian Cancer Species and Precancerous Landscape. Am. J. Pathol. 2021, 191, 26–39. [Google Scholar] [CrossRef] [PubMed]
- Wu, R.; Wang, P.; Lin, S.; Zhang, M.; Song, Q.; Chu, T.; Wang, B.G.; Kurman, R.J.; Vang, R.; Kinzler, K.; et al. Genomic Landscape and Evolutionary Trajectories of Ovarian Cancer Precursor Lesions. J. Pathol. 2019, 248, 41–50. [Google Scholar] [CrossRef]
- Asaka, S.; Davis, C.; Lin, S.-F.; Wang, T.-L.; Heaphy, C.M.; Shih, I.-M. Analysis of Telomere Lengths in P53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. Am. J. Surg. Pathol. 2019, 43, 1083–1091. [Google Scholar] [CrossRef]
- Bashashati, A.; Ha, G.; Tone, A.; Ding, J.; Prentice, L.M.; Roth, A.; Rosner, J.; Shumansky, K.; Kalloger, S.; Senz, J.; et al. Distinct Evolutionary Trajectories of Primary High-Grade Serous Ovarian Cancers Revealed through Spatial Mutational Profiling. J. Pathol. 2013, 231, 21–34. [Google Scholar] [CrossRef]
- Buis, C.C.; van Leeuwen, F.E.; Mooij, T.M.; Burger, C.W. Increased Risk for Ovarian Cancer and Borderline Ovarian Tumours in Subfertile Women with Endometriosis. Hum. Reprod. Oxf. Engl. 2013, 28, 3358–3369. [Google Scholar] [CrossRef]
- Hermens, M.; van Altena, A.M.; Bulten, J.; Siebers, A.G.; Bekkers, R.L.M. Increased Association of Ovarian Cancer in Women with Histological Proven Endosalpingiosis. Cancer Epidemiol. 2020, 65, 101700. [Google Scholar] [CrossRef]
- Mortlock, S.; Corona, R.I.; Kho, P.F.; Pharoah, P.; Seo, J.H.; Freedman, M.L.; Gayther, S.A.; Siedhoff, M.T.; Rogers, P.A.W.; Leuchter, R.; et al. A Multi-Level Investigation of the Genetic Relationship between Endometriosis and Ovarian Cancer Histotypes. Cell Rep. Med. 2022, 3, 100542. [Google Scholar] [CrossRef]
- Munksgaard, P.S.; Blaakaer, J. The Association between Endometriosis and Ovarian Cancer: A Review of Histological, Genetic and Molecular Alterations. Gynecol. Oncol. 2012, 124, 164–169. [Google Scholar] [CrossRef]
- Pearce, C.L.; Templeman, C.; Rossing, M.A.; Lee, A.; Near, A.M.; Webb, P.M.; Nagle, C.M.; Doherty, J.A.; Cushing-Haugen, K.L.; Wicklund, K.G.; et al. Association between Endometriosis and Risk of Histological Subtypes of Ovarian Cancer: A Pooled Analysis of Case–Control Studies. Lancet Oncol. 2012, 13, 385–394. [Google Scholar] [CrossRef]
- Bulletti, C.; Coccia, M.E.; Battistoni, S.; Borini, A. Endometriosis and Infertility. J. Assist. Reprod. Genet. 2010, 27, 441–447. [Google Scholar] [CrossRef]
- Taylor, H.S.; Kotlyar, A.M.; Flores, V.A. Endometriosis Is a Chronic Systemic Disease: Clinical Challenges and Novel Innovations. Lancet Br. Ed. 2021, 397, 839–852. [Google Scholar] [CrossRef]
- Sampson, J. Metastatic or Embolic Endometriosis, Due to the Menstrual Dissemination of Endometrial Tissue, into the Venous Circulation. Am. J. Pathol. 1927, 3, 93–U42. [Google Scholar]
- Rock, J.A.; Parmley, T.H.; King, T.M.; Laufe, L.E.; Su, B.C. Endometriosis and The Development of Tuboperitoneal Fistulas After Tubal Ligation. Fertil. Steril. 1981, 35, 16–20. [Google Scholar] [CrossRef]
- Donnez, J.; Casanas-Roux, F.; Ferin, J.; Thomas, K. Tubal Polyps, Epithelial Inclusions, and Endometriosis after Tubal Sterilization. Fertil. Steril. 1984, 41, 564–568. [Google Scholar] [CrossRef]
- Anglesio, M.S.; Papadopoulos, N.; Ayhan, A.; Nazeran, T.M.; Noë, M.; Horlings, H.M.; Lum, A.; Jones, S.; Senz, J.; Seckin, T.; et al. Cancer-Associated Mutations in Endometriosis without Cancer. N. Engl. J. Med. 2017, 376, 1835–1848. [Google Scholar] [CrossRef]
- Mangili, G.; Bergamini, A.; Taccagni, G.; Gentile, C.; Panina, P.; Viganò, P.; Candiani, M. Unraveling the Two Entities of Endometrioid Ovarian Cancer: A Single Center Clinical Experience. Gynecol. Oncol. 2012, 126, 403–407. [Google Scholar] [CrossRef]
- Li, Q.; Sun, Y.; Zhang, X.; Wang, L.; Wu, W.; Wu, M.; Meng, C.; Liu, G. Endometriosis-Associated Ovarian Cancer Is a Single Entity with Distinct Clinicopathological Characteristics. Cancer Biol. Ther. 2019, 20, 1029–1034. [Google Scholar] [CrossRef]
- Taylor, H.; Costigan, D. Ovarian Clear Cell Carcinoma: An Overview of Key Histopathologic Features. Int. J. Gynecol. Cancer 2023, 33, 843–844. [Google Scholar] [CrossRef]
- Takano, M.; Kikuchi, Y.; Yaegashi, N.; Kuzuya, K.; Ueki, M.; Tsuda, H.; Suzuki, M.; Kigawa, J.; Takeuchi, S.; Tsuda, H.; et al. Clear Cell Carcinoma of the Ovary: A Retrospective Multicentre Experience of 254 Patients with Complete Surgical Staging. Br. J. Cancer 2006, 94, 1369–1374. [Google Scholar] [CrossRef]
- Ho, C.-M.; Huang, Y.-J.; Chen, T.-C.; Huang, S.-H.; Liu, F.-S.; Chang Chien, C.-C.; Yu, M.-H.; Mao, T.-L.; Wang, T.-Y.; Hsieh, C.-Y. Pure-Type Clear Cell Carcinoma of the Ovary as a Distinct Histological Type and Improved Survival in Patients Treated with Paclitaxel-Platinum-Based Chemotherapy in Pure-Type Advanced Disease. Gynecol. Oncol. 2004, 94, 197–203. [Google Scholar] [CrossRef]
- Scarfone, G.; Bergamini, A.; Noli, S.; Villa, A.; Cipriani, S.; Taccagni, G.; Vigano, P.; Candiani, M.; Parazzini, F.; Mangili, G. Characteristics of Clear Cell Ovarian Cancer Arising from Endometriosis: A Two Center Cohort Study. Gynecol. Oncol. 2014, 133, 480–484. [Google Scholar] [CrossRef]
- Anglesio, M.S.; Bashashati, A.; Wang, Y.K.; Senz, J.; Ha, G.; Yang, W.; Aniba, M.R.; Prentice, L.M.; Farahani, H.; Li Chang, H.; et al. Multifocal Endometriotic Lesions Associated with Cancer Are Clonal and Carry a High Mutation Burden. J. Pathol. 2015, 236, 201–209. [Google Scholar] [CrossRef]
- Jones, S.; Wang, T.-L.; Shih, I.-M.; Mao, T.-L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A.; Vogelstein, B.; et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science 2010, 330, 228–231. [Google Scholar] [CrossRef]
- Wiegand, K.C.; Shah, S.P.; Al-Agha, O.M.; Zhao, Y.; Tse, K.; Zeng, T.; Senz, J.; McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E.; et al. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. N. Engl. J. Med. 2010, 363, 1532–1543. [Google Scholar] [CrossRef]
- Krämer, P.; Talhouk, A.; Brett, M.A.; Chiu, D.S.; Cairns, E.S.; Scheunhage, D.A.; Hammond, R.F.; Farnell, D.; Nazeran, T.M.; Grube, M.; et al. Endometrial Cancer Molecular Risk Stratification Is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin. Cancer Res. 2020, 26, 5400–5410. [Google Scholar] [CrossRef]
- Fonseca, M.A.S.; Haro, M.; Wright, K.N.; Lin, X.; Abbasi, F.; Sun, J.; Hernandez, L.; Orr, N.L.; Hong, J.; Choi-Kuaea, Y.; et al. Single-Cell Transcriptomic Analysis of Endometriosis. Nat. Genet. 2023, 55, 255–267. [Google Scholar] [CrossRef]
- Sieh, W.; Salvador, S.; McGuire, V.; Weber, R.P.; Terry, K.L.; Rossing, M.A.; Risch, H.; Wu, A.H.; Webb, P.M.; Moysich, K.; et al. Tubal Ligation and Risk of Ovarian Cancer Subtypes: A Pooled Analysis of Case-Control Studies. Int. J. Epidemiol. 2013, 42, 579–589. [Google Scholar] [CrossRef]
- Catanzarite, T.; Eskander, R.N. Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How? Female Pelvic Med. Reconstr. Surg. 2020, 26, 401–406. [Google Scholar] [CrossRef]
- Hanley, G.E.; McAlpine, J.N.; Cheifetz, R.; Schrader, K.A.; McCullum, M.; Huntsman, D. Selected Medical Interventions in Women With a Deleterious Brca Mutation: A Population-Based Study in British Columbia. Curr. Oncol. 2019, 26, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Jacobson, M.; Coakley, N.; Bernardini, M.; Branco, K.-A.; Elit, L.; Ferguson, S.; Kim, R. Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes: A Clinical Practice Guideline. Hered. Cancer Clin. Pract. 2021, 19, 39. [Google Scholar] [CrossRef] [PubMed]
- Eleje, G.U.; Eke, A.C.; Ezebialu, I.U.; Ikechebelu, J.I.; Ugwu, E.O.; Okonkwo, O.O. Risk-Reducing Bilateral Salpingo-Oophorectomy in Women with BRCA1 or BRCA2 Mutations. Cochrane Database Syst. Rev. 2018, 8, CD012464. [Google Scholar] [CrossRef] [PubMed]
- Parker, W.H.; Broder, M.S.; Chang, E.; Feskanich, D.; Farquhar, C.; Liu, Z.; Shoupe, D.; Berek, J.S.; Hankinson, S.; Manson, J.E. Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study. Obstet. Gynecol. N. Y. 1953 2009, 113, 1027–1037. [Google Scholar] [CrossRef] [PubMed]
- Parker, W.H.; Feskanich, D.; Broder, M.S.; Chang, E.; Shoupe, D.; Farquhar, C.M.; Berek, J.S.; Manson, J.E. Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses’ Health Study. Obstet. Gynecol. N. Y. 1953 2013, 121, 709–716. [Google Scholar] [CrossRef]
- Faubion, S.S.; Kuhle, C.L.; Shuster, L.T.; Rocca, W.A. Long-Term Health Consequences of Premature or Early Menopause and Considerations for Management. Climacteric 2015, 18, 483–491. [Google Scholar] [CrossRef]
- Daly, M.B.; Pal, T.; Berry, M.P.; Buys, S.S.; Dickson, P.; Domchek, S.M.; Elkhanany, A.; Friedman, S.; Goggins, M.; Hutton, M.L.; et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021, 19, 77–102. [Google Scholar] [CrossRef]
- Finch, A.P.M.; Lubinski, J.; Møller, P.; Singer, C.F.; Karlan, B.; Senter, L.; Rosen, B.; Maehle, L.; Ghadirian, P.; Cybulski, C.; et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J. Clin. Oncol. 2014, 32, 1547–1553. [Google Scholar] [CrossRef]
- Le Page, C.; Rahimi, K.; Köbel, M.; Tonin, P.N.; Meunier, L.; Portelance, L.; Bernard, M.; Nelson, B.H.; Bernardini, M.Q.; Bartlett, J.M.S.; et al. Characteristics and Outcome of the COEUR Canadian Validation Cohort for Ovarian Cancer Biomarkers. BMC Cancer 2018, 18, 347. [Google Scholar] [CrossRef]
- Smith, R.; Mettlin, C.; Eyre, H. Key Criteria in the Decision to Screen. In Holland-Frei Cancer Medicine, 6th ed.; BC Decker: Hamilton, ON, Canada, 2003. [Google Scholar]
- Henderson, J.T.; Webber, E.M.; Sawaya, G.F. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018, 319, 595. [Google Scholar] [CrossRef]
- Hanley, G.E.; McAlpine, J.N.; Pearce, C.L.; Miller, D. The Performance and Safety of Bilateral Salpingectomy for Ovarian Cancer Prevention in the United States. Am. J. Obstet. Gynecol. 2017, 216, 270.e1–270.e9. [Google Scholar] [CrossRef] [PubMed]
- McAlpine, J.N.; Hanley, G.E.; Woo, M.M.M.; Tone, A.A.; Rozenberg, N.; Swenerton, K.D.; Gilks, C.B.; Finlayson, S.J.; Huntsman, D.G.; Miller, D.M.; et al. Opportunistic Salpingectomy: Uptake, Risks, and Complications of a Regional Initiative for Ovarian Cancer Prevention. Am. J. Obstet. Gynecol. 2014, 210, 471.e1–471.e11. [Google Scholar] [CrossRef] [PubMed]
- Hanley, G.E.; Kwon, J.S.; Finlayson, S.J.; Huntsman, D.G.; Miller, D.; McAlpine, J.N. Extending the Safety Evidence for Opportunistic Salpingectomy in Prevention of Ovarian Cancer: A Cohort Study from British Columbia, Canada. Am. J. Obstet. Gynecol. 2018, 219, 172.e1–172.e8. [Google Scholar] [CrossRef] [PubMed]
- Roeckner, J.T.; Sawangkum, P.; Sanchez-Ramos, L.; Duncan, J.R. Salpingectomy at the Time of Cesarean Delivery: A Systematic Review and Meta-Analysis. Obstet. Gynecol. 2020, 135, 550–557. [Google Scholar] [CrossRef] [PubMed]
- Gelderblom, M.E.; IntHout, J.; Dagovic, L.; Hermens, R.P.M.G.; Piek, J.M.J.; de Hullu, J.A. The Effect of Opportunistic Salpingectomy for Primary Prevention of Ovarian Cancer on Ovarian Reserve: A Systematic Review and Meta-Analysis. Maturitas 2022, 166, 21–34. [Google Scholar] [CrossRef] [PubMed]
- Hanley, G.E.; Kwon, J.S.; McAlpine, J.N.; Huntsman, D.G.; Finlayson, S.J.; Miller, D. Examining Indicators of Early Menopause Following Opportunistic Salpingectomy: A Cohort Study from British Columbia, Canada. Am. J. Obstet. Gynecol. 2020, 223, 221.e1–221.e11. [Google Scholar] [CrossRef] [PubMed]
- Collins, E.; Strandell, A.; Granåsen, G.; Idahl, A. Menopausal Symptoms and Surgical Complications after Opportunistic Bilateral Salpingectomy, a Register-Based Cohort Study. Am. J. Obstet. Gynecol. 2019, 220, 85.e1–85.e10. [Google Scholar] [CrossRef] [PubMed]
- Wagar, M.K.; Forlines, G.L.; Moellman, N.; Carlson, A.; Matthews, M.; Williams, M. Postpartum Opportunistic Salpingectomy Compared With Bilateral Tubal Ligation After Vaginal Delivery for Ovarian Cancer Risk Reduction: A Cost-Effectiveness Analysis. Obstet. Gynecol. 2023, 141, 819–827. [Google Scholar] [CrossRef]
- Venkatesh, K.K.; Clark, L.H.; Stamilio, D.M. Cost-Effectiveness of Opportunistic Salpingectomy vs Tubal Ligation at the Time of Cesarean Delivery. Am. J. Obstet. Gynecol. 2019, 220, 106.e1–106.e10. [Google Scholar] [CrossRef]
- Kwon, J.S.; McAlpine, J.N.; Hanley, G.E.; Finlayson, S.J.; Cohen, T.; Miller, D.M.; Gilks, C.B.; Huntsman, D.G. Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy. Obstet. Gynecol. N. Y. 1953 2015, 125, 338–345. [Google Scholar] [CrossRef]
- Lessard-Anderson, C.R.; Handlogten, K.S.; Molitor, R.J.; Dowdy, S.C.; Cliby, W.A.; Weaver, A.L.; Sauver, J.S.; Bakkum-Gamez, J.N. Effect of Tubal Sterilization Technique on Risk of Serous Epithelial Ovarian and Primary Peritoneal Carcinoma. Gynecol. Oncol. 2014, 135, 423–427. [Google Scholar] [CrossRef] [PubMed]
- Madsen, C.; Baandrup, L.; Dehlendorff, C.; Kjær, S.K. Tubal Ligation and Salpingectomy and the Risk of Epithelial Ovarian Cancer and Borderline Ovarian Tumors: A Nationwide Case-Control Study. Acta Obstet. Gynecol. Scand. 2015, 94, 86–94. [Google Scholar] [CrossRef] [PubMed]
- Falconer, H.; Yin, L.; Gronberg, H.; Altman, D. Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study. JNCI J. Natl. Cancer Inst. 2015, 107, dju410. [Google Scholar] [CrossRef] [PubMed]
- Duus, A.H.; Zheng, G.; Baandrup, L.; Faber, M.T.; Kjær, S.K. Risk of Ovarian Cancer after Salpingectomy and Tubal Ligation: Prospects on Histology and Time since the Procedure. Gynecol. Oncol. 2023, 177, 125–131. [Google Scholar] [CrossRef] [PubMed]
- Giannakeas, V.; Murji, A.; Lipscombe, L.L.; Narod, S.A.; Kotsopoulos, J. Salpingectomy and the Risk of Ovarian Cancer in Ontario. JAMA Netw. Open 2023, 6, e2327198. [Google Scholar] [CrossRef] [PubMed]
- Ntoumanoglou-Schuiki, A.; Tomasch, G.; Laky, R.; Taumberger, N.; Bjelic-Radisic, V.; Tamussino, K. Opportunistic Prophylactic Salpingectomy for Prevention of Ovarian Cancer: What Do National Societies Advise? Eur. J. Obstet. Gynecol. Reprod. Biol. 2018, 225, 110–112. [Google Scholar] [CrossRef] [PubMed]
- Hanley, G.E.; Niu, J.; Han, J.; Fung, S.; Bryant, H.; Kwon, J.S.; Huntsman, D.G.; Finlayson, S.J.; McAlpine, J.N.; Miller, D.; et al. Opportunistic Salpingectomy between 2011 and 2016: A Descriptive Analysis. CMAJ Open 2022, 10, E466–E475. [Google Scholar] [CrossRef]
- Runnebaum, I.B.; Kather, A.; Vorwergk, J.; Cruz, J.J.; Mothes, A.R.; Beteta, C.R.; Boer, J.; Keller, M.; Pölcher, M.; Mustea, A.; et al. Ovarian Cancer Prevention by Opportunistic Salpingectomy Is a New de Facto Standard in Germany. J. Cancer Res. Clin. Oncol. 2023, 149, 6953–6966. [Google Scholar] [CrossRef]
- Gelderblom, M.E.; Jaspers, V.; Akkermans, R.P.; Slangen, B.; Oei, A.L.M.; van Ginkel, A.A.; Ngo, H.; IntHout, J.; Hermens, R.P.M.G.; de Hullu, J.A.; et al. First Step in Implementation of Opportunistic Salpingectomy for Prevention of Ovarian Cancer: Current Care and Its Determinants. Acta Obstet. Gynecol. Scand. 2023, 102, 257–269. [Google Scholar] [CrossRef]
- Karia, P.S.; Joshu, C.E.; Visvanathan, K. Uptake and Predictors of Opportunistic Salpingectomy for Ovarian Cancer Risk Reduction in the United States. Cancer Prev. Res. 2021, 14, 1101–1110. [Google Scholar] [CrossRef]
- Matsuo, K.; Chen, L.; Matsuzaki, S.; Mandelbaum, R.S.; Ciesielski, K.M.; Silva, J.P.; Klar, M.; Roman, L.D.; Accordino, M.K.; Melamed, A.; et al. Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy for Ovarian Cancer Prevention: A Cost-Effectiveness Analysis. Ann. Surg. 2022. Publish Ahead of Print. [Google Scholar] [CrossRef] [PubMed]
- Tomasch, G.; Lemmerer, M.; Oswald, S.; Uranitsch, S.; Schauer, C.; Schütz, A.-M.; Bliem, B.; Berger, A.; Lang, P.F.J.; Rosanelli, G.; et al. Prophylactic Salpingectomy for Prevention of Ovarian Cancer at the Time of Elective Laparoscopic Cholecystectomy. Br. J. Surg. 2020, 107, 519–524. [Google Scholar] [CrossRef] [PubMed]
- Tomasch, G.; Bliem, B.; Lemmerer, M.; Oswald, S.; Uranitsch, S.; Greimel, E.R.; Bjelic-Radisic, V.; Rosanelli, G.; Uranues, S.; Tamussino, K. Would Women Accept Opportunistic (Prophylactic) Salpingectomy at the Time of Nongynecologic Surgery to Prevent Development of Ovarian Cancer? Surgery 2018, 164, 931–934. [Google Scholar] [CrossRef] [PubMed]
- Stone, R.; Sakran, J.V.; Long Roche, K. Salpingectomy in Ovarian Cancer Prevention. JAMA 2023, 329, 2015–2016. [Google Scholar] [CrossRef] [PubMed]
- Pearce, C.L.; Rossing, M.A.; Lee, A.W.; Ness, R.B.; Webb, P.M.; for Australian Cancer Study (Ovarian Cancer); and Australian Ovarian Cancer Study Group; Chenevix-Trench, G.; Jordan, S.M.; Stram, D.A.; et al. Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 2013, 22, 880–890. [Google Scholar] [CrossRef] [PubMed]
- Kar, S.P.; Berchuck, A.; Gayther, S.A.; Goode, E.L.; Moysich, K.B.; Pearce, C.L.; Ramus, S.J.; Schildkraut, J.M.; Sellers, T.A.; Pharoah, P.D.P. Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. Cancer Epidemiol. Biomarkers Prev. 2018, 27, 395–404. [Google Scholar] [CrossRef] [PubMed]
- Carver, T.; Hartley, S.; Lee, A.; Cunningham, A.P.; Archer, S.; Babb de Villiers, C.; Roberts, J.; Ruston, R.; Walter, F.M.; Tischkowitz, M.; et al. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol. Biomark. Prev. 2021, 30, 469–473. [Google Scholar] [CrossRef]
- Lee, A.; Yang, X.; Tyrer, J.; Gentry-Maharaj, A.; Ryan, A.; Mavaddat, N.; Cunningham, A.P.; Carver, T.; Archer, S.; Leslie, G.; et al. Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors. J. Med. Genet. 2021, 59, 632–643. [Google Scholar] [CrossRef]
- Steenbeek, M.P.; Van Lieshout, L.A.M.; Aarts, J.W.M.; Piek, J.M.J.; Coppus, S.F.P.J.; Massuger, L.F.A.G.; Hermens, R.P.M.G.; De Hullu, J.A. Factors Influencing Decision-Making around Opportunistic Salpingectomy: A Nationwide Survey. J. Gynecol. Oncol. 2019, 30, e2. [Google Scholar] [CrossRef]
- van Lieshout, L.A.M.; Gelderblom, M.E.; de Hullu, J.A.; The, R.; van Ginkel, A.A.; Oerlemans, A.J.M.; Smeets, K.M.W.H.; Schreurs, M.P.H.; Piek, J.M.J.; Hermens, R.P.M.G. Primary Prevention of Ovarian Cancer: A Patient Decision Aid for Opportunistic Salpingectomy. Am. J. Obstet. Gynecol. 2022, 226, 234.e1–234.e14. [Google Scholar] [CrossRef]
- Gelderblom, M.E.; Van Lieshout, L.A.M.; Piek, J.M.J.; De Hullu, J.A.; Hermens, R.P.M.G. Patients’ and Professionals’ Perspectives on Implementation of Opportunistic Salpingectomy: A Mixed-Method Study. BMC Health Serv. Res. 2021, 21, 736. [Google Scholar] [CrossRef] [PubMed]
- Kahn, R.M.; Gordhandas, S.; Godwin, K.; Stone, R.L.; Worley, M.J.; Lu, K.H.; Long Roche, K.C. Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review. JAMA Surg. 2023, 158, 1204–1211. [Google Scholar] [CrossRef] [PubMed]
- Karia, P.S.; Huang, Y.; Tehranifar, P.; Visvanathan, K.; Wright, J.D.; Genkinger, J.M. Racial and Ethnic Differences in the Adoption of Opportunistic Salpingectomy for Ovarian Cancer Prevention in the United States. Am. J. Obstet. Gynecol. 2022, 227, 257.e1–257.e22. [Google Scholar] [CrossRef] [PubMed]
- Racial Disparities in Sterilization Procedure Performed at Time of Cesarean Section. Available online: https://pubmed.ncbi.nlm.nih.gov/36351447/#:~:text=After%20adjusting%20for%20differences%2C%20Black,interval%3A%200.36%2D0.75 (accessed on 15 August 2023).
- Stern, A.M. STERILIZED in the Name of Public Health: Race, Immigration, and Reproductive Control in Modern California. Am. J. Public. Health 2005, 95, 1128–1138. [Google Scholar] [CrossRef]
- Standing Senate Committee on Human Rights. Forced and Coerced Sterilization of Persons in Canada. June 2021. Available online: https://sencanada.ca/content/sen/committee/432/RIDR/reports/ForcedSterilization_Report_FINAL_E.pdf (accessed on 15 August 2023).
- Patel, P. Forced Sterilization of Women as Discrimination. Public. Health Rev. 2017, 38, 15. [Google Scholar] [CrossRef]
- Borrero, S.; Zite, N.; Potter, J.E.; Trussell, J. Medicaid Policy on Sterilization—Anachronistic or Still Relevant? N. Engl. J. Med. 2014, 370, 102–104. [Google Scholar] [CrossRef]
- Arora, K.S.; Chua, A.; Miller, E.; Boozer, M.; Serna, T.; Bullington, B.W.; White, K.; Gunzler, D.D.; Bailit, J.L.; Berg, K. Medicaid and Fulfillment of Postpartum Permanent Contraception Requests. Obstet. Gynecol. 2023, 141, 918–925. [Google Scholar] [CrossRef]
- Naumann, R.W.; Hughes, B.N.; Brown, J.; Drury, L.K.; Herzog, T.J. The Impact of Opportunistic Salpingectomy on Ovarian Cancer Mortality and Healthcare Costs: A Call for Universal Insurance Coverage. Am. J. Obstet. Gynecol. 2021, 225, 397.e1–397.e6. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sowamber, R.; Lukey, A.; Huntsman, D.; Hanley, G. Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. Curr. Oncol. 2023, 30, 10179-10194. https://doi.org/10.3390/curroncol30120741
Sowamber R, Lukey A, Huntsman D, Hanley G. Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. Current Oncology. 2023; 30(12):10179-10194. https://doi.org/10.3390/curroncol30120741
Chicago/Turabian StyleSowamber, Ramlogan, Alexandra Lukey, David Huntsman, and Gillian Hanley. 2023. "Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs" Current Oncology 30, no. 12: 10179-10194. https://doi.org/10.3390/curroncol30120741